-
Mashup Score: 36Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention - 5 month(s) ago
For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. | For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. For Gilead, it serves as one of two pieces for a potential FDA filing. For GSK, it means a major competitor could be looming around the corner.
Source: www.fiercepharma.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 36Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention - 5 month(s) ago
For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. | For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. For Gilead, it serves as one of two pieces for a potential FDA filing. For GSK, it means a major competitor could be looming around the corner.
Source: www.fiercepharma.comCategories: General Medicine News, Partners & KOLsTweet-
LENACAPAVIR: Huge news. Capsid inhibitor injected into abdomen (with 2 oral loading doses) subcutaneously every 6 months. Large PrEP trial >2000 women compared LEN to 2 oral regimens (TDF/FTC; TAF/FTC). LEN 100% superior to oral arms; no infections LEN arm https://t.co/RTvPyGwjh6
-
-
Mashup Score: 0Kansas AG accuses Pfizer of misrepresenting COVID vaccine, hiding safety risks in lawsuit - 5 month(s) ago
As controversy surrounding the COVID-19 pandemic gets dredged up again following a wave of renewed
Source: www.fiercepharma.comCategories: General Medicine News, Infectious DiseaseTweet-
Just overt pandering with no basis in reality https://t.co/t2beabU4Pc
-
-
Mashup Score: 36Watch out, GSK. Gilead’s twice-yearly PrEP drug shows 100% efficacy for HIV prevention - 5 month(s) ago
For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. | For the first time, an HIV PrEP drug candidate has shown zero infections in a phase 3 trial. For Gilead, it serves as one of two pieces for a potential FDA filing. For GSK, it means a major competitor could be looming around the corner.
Source: www.fiercepharma.comCategories: General Medicine News, Partners & KOLsTweet-
LENACAPAVIR: Huge news. Capsid inhibitor injected into abdomen (with 2 oral loading doses) subcutaneously every 6 months. Large PrEP trial >2000 women compared LEN to 2 oral regimens (TDF/FTC; TAF/FTC). LEN 100% superior to oral arms; no infections LEN arm https://t.co/RTvPyGwjh6
-
-
Mashup Score: 2ALS market to grow 15% by 2029, boosted by pharmas’ awareness-raising, drug development work: report - 5 month(s) ago
The amyotrophic lateral sclerosis (ALS) market is expected to see significant growth in the coming years, but there is still plenty of work to be done within the space, according to a new analyst < | The amyotrophic lateral sclerosis market is expected to see significant growth in the coming years, but there is still plenty of work to be done within the space, according to a new analyst report.
Source: www.fiercepharma.comCategories: General Medicine News, Rare DiseaseTweet-
Biting my tongue as I read this... ALS market to grow 15% by 2029, boosted by pharmas’ awareness-raising, drug development work: report https://t.co/389GEGhNub
-
-
Mashup Score: 7Analysts predict myeloma market will hit $33B by 2030—and tip one company to take the lion's share - 5 month(s) ago
The multiple myeloma market is booming. | The multiple myeloma market is booming. Bloomberg Intelligence (BI) forecasts sales will hit $33 billion in 2030, up almost $10 billion on last year, as Johnson & Johnson wrestles control of the blood cancer market from Bristol Myers Squibb.
Source: www.fiercepharma.comCategories: General Medicine News, Hem/OncsTweet-
@AaronGoodman33 Wonder why https://t.co/SMuSNuGILb
-
-
Mashup Score: 0Lilly wins NICE endorsement for tirzepatide in obesity—with a catch - 5 month(s) ago
A little less than a year after Eli Lilly won the blessing of England’s drug value watchdog for tirzepatide in Type 2 diabetes, the National Institute for Health and Care Excellence (NICE) has retu | A little less than a year after Eli Lilly won the blessing of England’s drug value watchdog for tirzepatide in Type 2 diabetes, the National Institute for Health and Care Excellence (NICE) has returned with an endorsement in obesity. However, this time, the organization’s green light has some caveats.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
.@EliLillyandCo wins #UK NICE endorsement for tirzepatide in #obesity—with a catch | #GLP1 https://t.co/dTuKfsWkxX
-
-
Mashup Score: 1Would BIO support a biosecurity bill targeting drug developers? Hear CEO John Crowley’s response - 5 month(s) ago
Two leaders on the House’s Select Committee on the CCP last week
Source: www.fiercepharma.comCategories: General Medicine News, Rare DiseaseTweet-
RT @FiercePharma: Would BIO support a biosecurity bill targeting drug developers? Hear CEO John Crowley’s response https://t.co/uTEsEdjG8s
-
-
Mashup Score: 0AbbVie's Humira 2.0 drug couple Skyrizi, Rinvoq will help sales rebound amid biosimilar onslaught: report - 5 month(s) ago
AbbVie’s Humira sales slipped last year as the Big Pharma dealt with the first real generic erosion of its immunology megablockbuster, but its backup meds will be more than enough to not just shore | AbbVie’s Humira sales slipped last year as the Big Pharma dealt with the first real generic erosion of its immunology megablockbuster, but its backup meds will be more than enough to not just shore up its revenue—but also boost its top line.
Source: www.fiercepharma.comCategories: General Medicine News, General HCPsTweet-
.@AbbVie's Humira 2.0 drug couple Skyrizi, Rinvoq will help sales rebound amid #biosimilar onslaught: report https://t.co/fYAEnubr55
-
-
Mashup Score: 1Amarin's CEO resigns, leaving former interim chief to take over struggling drugmaker - 5 month(s) ago
After Amarin’s tussle with investor group Sarissa Capital led to a restructuring and a board shuffle, the struggling drugmaker is undergoing its third CEO shake-up in just over a year.
Source: www.fiercepharma.comCategories: General Medicine News, Expert PicksTweet-
RT @FiercePharma: Amarin CEO resigns, leaving former interim chief to take over struggling drugmaker https://t.co/9uHhpcEkpV
-
LENACAPAVIR: Huge news. Capsid inhibitor injected into abdomen (with 2 oral loading doses) subcutaneously every 6 months. Large PrEP trial >2000 women compared LEN to 2 oral regimens (TDF/FTC; TAF/FTC). LEN 100% superior to oral arms; no infections LEN arm https://t.co/RTvPyGwjh6